Drug intelligence / Profile preview

gamma-MSH

Development stage
Preclinical
Lead developer
Teleost Biopharmaceuticals
Modality
Peptides
Administration
Transdermal, Topical
01

Overview

gamma-MSH (g-MSH) is a synthetic melanocyte-stimulating hormone peptide analogue developed by **Teleost Biopharmaceuticals** in collaboration with the **University of Arizona**. The drug is a stable synthetic version of the naturally occurring peptide derived from pro-opiomelanocortin (POMC). It acts as an agonist of the **melanocortin-1 receptor (MC1-R)** located on melanocytes, where it triggers melanogenesis (the production of melanin) in epidermal tissue. A key feature of this synthetic analogue is its ability to induce melanin production without causing homologous desensitization of the MC1-R receptors and without requiring UV exposure. The peptide is designed for transdermal delivery, either via a multi-day skin patch or topical formulations like creams and lotions, and is intended for applications in tanning, sun protection, and general skin care. Notably, the peptide does not cross the blood-brain barrier.

Other names
g-MSHmelanin stimulating hormonesynthetic g-MSH peptide-based skin patchgamma-melanocyte stimulating hormone
02

Targets

MC1R (Melanocortin Type 1 Receptor)MC3R (Melanocortin Receptor Type 3)MC4R (Melanocortin 4 receptor)MC5R (Melanocortin 5 Receptor)

Beyond the preview

Go deeper on gamma-MSH.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on gamma-MSH.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call